„和任何疫苗说明书一样,它指出,目前尚不清楚该疫苗对男女双方生育能力、癌症发生可能性以及自身免疫性疾病发生可能性的影响。也就是说?说明书说:“实际上,我们对这种疫苗的作用一无所知。””Jak w każdej ulotce dotyczącej szczepień wskazuje ona na to, że nieznany jest jej wpływ na płodność obu płci, na możliwość występowania nowotworów czy na możliwe wystąpienie chorób z grupy autoagresji. Czyli? Ulotka mówi: „o działaniu tej szczepionki, tak naprawdę niczego nie wiemy”.
„几位经验丰富的病理学家分享了他们的观察:自开始接种 COVID-19 疫苗以来,癌症病例数量上升,恶性程度也有所增加(例如,见[94])。许多此类病例似乎涉及癌症重新激活,有时是在数十年后;这些癌症此前曾被认为已经治愈。使癌细胞受到控制的细胞免疫机制,基本上与控制和对抗病毒感染的机制相同。因此,这些报告也表明,接种疫苗后出现了显著的免疫抑制。”Several experienced pathologists have shared their observations on rising case numbers and increased malignancy of cancers since the beginning of the COVID-19 vaccinations (see e.g. [94]). Many such cases seem to involve the reactivation of cancers, sometimes after decades, which had been considered cured. The mechanisms of cellular immunity that keep cancer cells in check are basically the same as those which control and combat viral infections. Therefore, these reports also point to significant immunosuppression after vaccination.
„因此,这些报告也表明,接种疫苗后出现了显著的免疫抑制。3.5.2 可能的机制。如上所述,免疫抑制尚未被普遍认可为 COVID-19 疫苗接种造成的一项重大问题,而且我们没有发现任何已发表的……
3 mRNA 疫苗造成伤害的免疫学机制”Therefore, these reports also point to significant immunosuppression after vaccination. 3.5.2 Possible mechanisms. As noted above, immunosuppression is not yet commonly acknowledged as a significant problem caused by the COVID-19 vaccinations, and we are not aware of any published
3 Immunological mechanisms of harm by mRNA vaccines
„我们再次强调,任何形式的遗传毒性,无论剂量如何,都意味着存在一定的癌症和白血病风险。因此,频繁重复接种 COVID“加强针”的计划,以及将 mRNA 技术扩展到针对其他病原体或非传染性疾病的疫苗,都构成了显著的公共卫生风险。”We stress again that any form of genotoxicity, at any dose, implies a certain risk of cancer and leukemia. Thus, the prospect of frequently repeated COVID “booster shots,” as well as of extending mRNA technology to vaccines against other pathogens or non-infectious diseases, conjures up a significant public health risk.
研究经费政府、公共机构 · National Institute on Aging (R01AG076580)
作者与公司有关联吗?没有——作者如此声明
生产商是否参与协助研究?否
研究类型对人群的观察
参与人数121 676
“未注明”并不代表无人出资——数据库并不总会记录。
正分子医学医生怎么说?
Orthomolecular Medicine News Service
„Ozdemir K(2021)《COVID-19 疫苗接种前后健康女性氧化应激参数、微量元素和生活质量水平的比较》。美国国家医学图书馆 80。Pierce JD、Shen Q、Cintron SA、Hiebert JB(2021)《COVID-19 后综合征》。护理研究。Mondelli V、Pariante CM(2021)《神经免疫学能从哪些方面帮助我们理解长期 COVID 的症状?》《牛津开放免疫学》2:iqab004。Cumpstey AF、Clark AD、Santolini J 等(2021)《COVID-19:一种氧化还原疾病——压力大流行能教会我们什么是韧性,以及我们可以从活性物种相互作用组中学到哪些治疗方法》。 《抗氧化与氧化还原信号》35:1226-1268。Kalyanaraman, B。”Ozdemir K (2021) Comparison of Oxidative Stress Parameters, Trace, Element and Quality of Life Levels in Healthy Women Before and After Covid-19 Vaccines. US Nat. Lib. Med. 80. Pierce JD, Shen Q, Cintron SA, Hiebert JB (2021) Post-COVID-19 Syndrome. Nurs Res. Mondelli V, Pariante CM (2021) What can neuroimmunology teach us about the symptoms of long-COVID? Oxf Open Immunol 2:iqab004. Cumpstey AF, Clark AD, Santolini J, et al. (2021) COVID-19: A Redox Disease-What a Stress Pandemic Can Teach Us About Resilience and What We May Learn from the Reactive Species Interactome About Its Treatment. Antioxid Redox Signal 35:1226-1268. Kalyanaraman, B.
„(2023)《“刺突蛋白病”:COVID-19 刺突蛋白具有致病性,既可能来自病毒,也可能来自疫苗 mRNA》。《生物医学》11:2287。Ondruschka B、Heinrich F、Lindenmeyer M 等(2021)《SARS-CoV-2 B.1.1.7 谱系的多器官嗜性》。《国际法律医学杂志》135:2347-2349。Ping H、Zhang K、Wang Y 等(2021)《COVID-19 患者脾脏的细胞死亡与病理学发现》。《病理学研究与实践》227:153610。Morz M(2022)《病例报告:接种 BNT162b2 mRNA COVID-19 疫苗后发生多灶性坏死性脑炎和心肌炎》。《疫苗》10:1651。Macedo S、Pestana A、Santos L 等。”(2023) "Spikeopathy": COVID-19 spike protein is pathogenic, from both virus and vaccine mRNA. Biomedicines 11:2287. Ondruschka B, Heinrich F, Lindenmeyer M et al. (2021) Multiorgan tropism of SARS-CoV-2 lineage B.1.1.7. International Journal of Legal Medicine 135:2347-2349. Ping H, Zhang K, Wang Y et al. (2021) Cell death and pathological findings of the spleen in COVID-19 patients. Pathology, Research, and Practice 227:153610. Morz M (2022) A case report: multifocal necrotizing encephalitis and myocarditis after BNT162b2 mRNA vaccination against COVID-19. Vaccines 10:1651. Macedo S, Pestana A, Santos L et al.